Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: Clinical role

Annals of Oncology

Volumn 14, Issue 7, 2003, Pages 1135-1141

  Cimitan, M ^a   Buonadonna, A ^a   Cannizzaro, R ^a   Canzonieri, V ^a   Borsatti, E ^a   Ruffo, R ^a   De Apollonia, L ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

111In pentetreotide; Chromogranin A; Neuroendocrine tumors; Somatostatin receptor scintigraphy

Indexed keywords

CHROMOGRANIN A; PENTETATE INDIUM IN 111; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR RECURRENCE;

EID: 0041700078     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg279     Document Type: Article

References (23)

1. Cappella C, Heitz PU, Hofler H et al. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994; 55 (Suppl 3): 11-23.
2. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. World Health Organization International Histological Classification of Tumours, 2nd edition. Berlin: Springer 2000.
3. Stridsberg M, Oberg K, Li Q et al. Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
4. Nobels FR, Kwekkeboom DJ, Coopmans W et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoproteins hormones. J Clin Endocrinol Metab 1997; 82: 2622-2628.
5. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SWJ. Chromogranin A: its clinical value as marker of neuroendocrine tumors. Eur J Clin Invest 1998; 28: 431-440.
6. Baudin E, Gigliotti A, Duxcreux M et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102-1107.
7. 123I-Tyr3]octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
8. Schillaci O, Scopinaro F, Danieli R et al. Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids. Anticancer Res 1997; 17: 1753-1756.
9. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998; 25: 639-658.
10. Chiti A, Fanti S, Savelli G et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25: 1396-1403.
11. Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41: 1704-1713.
12. Goebel SU, Serrano J, Yu F et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer 1999; 85: 1470-1483.
13. Seregni E, Ferrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 2000; 44: 22-41.
14. Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000; 44: 3-12.
15. Boerman OC, Oyen WJG, Corstens FHM. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med 2000; 30: 195-208.
16. Kalkner KM, Janson ET, Nilsson S et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radio-ligand uptake and tumor markers. Cancer Res 1995; 55 (Suppl): 5801-5804.
17. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000; 44: 13-21.
18. Chiti A, Briganti V, Fanti S et al. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 2000; 44: 42-49.
19. Baduin E, Bidart JM, Bachelot A et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 2001; 12: 135-138.
20. Ferrari L, Seregni E, Bajetta E et al. The biological characteristics of chromogranin A and its role as circulating marker in neuroendocrine tumors. Anticancer Res 1999; 19: 3415-3428.
21. Bajetta E, Ferrari L, Martinetti A et al. Chromogranin A, neuron specific enolasi, carcinoembryogenic antigen and hydroxyndole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86: 858-865.
22. Gibril F, Reynolds JC, Chen CC et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localization on management in patients with gastrinomas. J Nucl Med 1999; 40: 539-553.
23. Stivanello M, Berruti A, Torta M et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 (Suppl 2): S73-S77.